ETF Building Blocks Channel Pfizer Vaccine Should Work Against Omicron, Just Less Efficiently By Karrie GordonNovember 30, 2021
ETF Building Blocks Channel Memeification of Biotech Stocks Shines Light on This ETF By Tom LydonNovember 24, 2021
ETF Building Blocks Channel Biotech Ready to Participate in Healthcare Bullishness By Tom LydonOctober 29, 2021
ETF Building Blocks Channel Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Channel Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
ETF Building Blocks Channel Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
ETF Building Blocks Channel Drug Pricing Reform Unlikely to Affect Smaller Biotech Companies By Tom LydonJune 24, 2021
ETF Building Blocks Channel Turn Healthcare Breakthroughs into ETF Gains with This Fund By Tom LydonJune 21, 2021
ETF Building Blocks Channel Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Channel As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Innovative ETFs Channel Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
ETF Building Blocks Channel Capture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO’ By Tom LydonFebruary 10, 2021
ETF Building Blocks Channel ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
ETF Building Blocks Channel Don’t Miss Out on Rampant Biotech Mergers with the SBIO ETF By Tom LydonJanuary 13, 2021
Innovative ETFs Channel Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020